Casgevy Insurance Denied? Appealing Your CRISPR Gene Therapy Claim

Casgevy (exagamglogene autotemcel, exa-cel) made history in December 2023 as the world's first approved CRISPR-based gene therapy. The FDA approved it for two serious blood disorders: sickle cell disease (SCD) with recurrent vaso-occlusive crises, and transfusion-dependent beta-thalassemia (TDT). A one-time treatment, Casgevy edits a patient's own stem cells to reactivate fetal hemoglobin production, addressing the root cause of both conditions. With a price tag near $2.2 million per treatment, insurance coverage denials are frequent and often based on the novelty of the CRISPR platform rather than on the clinical evidence.

If your claim for Casgevy has been denied, this guide will walk you through the appeal process, your rights, and the resources available to you.

Why Insurers Deny Casgevy

"Experimental" or "investigational" classification. CRISPR gene editing is a novel technology, and some insurers apply blanket "experimental" labels to any gene editing therapy. However, Casgevy holds full FDA approval — not conditional or temporary approval — which directly contradicts an experimental classification.

Step therapy requirements. For sickle cell disease, insurers may require proof of failure of hydroxyurea, blood transfusion therapy, or other standard treatments before considering Casgevy. While prior treatment history is clinically relevant, excessive step therapy requirements that go beyond FDA label criteria can be appealed.

Not in formulary. Specialty formularies often lag behind FDA approvals, particularly for novel platforms. A formulary exclusion is an administrative barrier, not a clinical determination, and should be challenged accordingly.

Transition of care issues. Some plans may deny coverage on grounds that Casgevy must be administered at a specialized treatment center that is not in-network. This requires negotiating single-case agreements for out-of-network access.

Medical necessity disputes based on disease severity. Insurers may challenge whether the patient's disease severity meets the threshold for coverage, requiring detailed documentation of vaso-occlusive crisis history or transfusion burden.

FDA Approval and What It Means

The FDA approved Casgevy on December 8, 2023, for patients 12 years and older with sickle cell disease with recurrent vaso-occlusive crises and for patients 12 years and older with transfusion-dependent beta-thalassemia. It was the first gene therapy based on CRISPR-Cas9 technology to receive regulatory approval anywhere in the world, simultaneously approved by the UK's MHRA.

Casgevy holds FDA Orphan Drug Designation for both indications, as well as Breakthrough Therapy Designation, Fast Track Designation, and Priority Review. Each of these designations signals the FDA's determination that the therapy addresses a serious unmet medical need with compelling evidence. An insurer's claim that it is "experimental" directly contradicts the FDA's regulatory findings.

Building Your Appeal

Hematologist documentation. Your treating physician should document your complete disease history: number and severity of vaso-occlusive crises per year (for SCD), transfusion burden (for TDT), hospitalizations, organ damage, opioid analgesic use, and quality-of-life impacts. This creates an undeniable medical necessity record.

Clinical trial data. The CLIMB SCD-121 and CLIMB THAL-111 trials published in the New England Journal of Medicine showed that the majority of Casgevy recipients were free of severe vaso-occlusive crises (for SCD) or transfusion-independent (for TDT) at follow-up. These results should be cited and attached.

Orphan drug and FDA designation documentation. Obtain official FDA documentation of Casgevy's approval, Orphan Drug Designation, and Breakthrough Therapy Designation from the FDA's website and include it with your appeal.

Step therapy exhaustion documentation. If step therapy is a denial reason, provide complete records of prior treatments, including hydroxyurea therapy with dose and duration, transfusion records, and documented adverse effects or inadequate responses.

Cost-effectiveness context. SCD and TDT cause substantial lifetime costs in hospitalizations, transfusions, chelation therapy, and chronic organ damage. Published cost-effectiveness analyses support Casgevy's value case, though the primary argument remains medical necessity.

Expedited Appeal Rights

Sickle cell disease with recurrent vaso-occlusive crises can be a life-threatening condition. If you have had recent hospitalizations, acute chest syndrome episodes, or other severe complications, your physician should document clinical urgency to qualify for an expedited internal appeal with a 72-hour decision timeline.

External Independent Review: Complete Guide" class="auto-link">External Review

If internal appeals fail, external review by an independent organization is your next step. For an FDA-approved, first-in-class CRISPR therapy backed by New England Journal of Medicine publications, external reviewers have strong grounds to overturn a denial based on "experimental" grounds. Request external review within the window specified in your denial notice.

Patient Assistance Programs

Vertex Pharmaceuticals and CRISPR Therapeutics, the co-developers of Casgevy, offer patient support services. Contact their patient access teams for information on financial assistance, insurance navigation support, and free drug programs for eligible patients.

NORD, the Sickle Cell Disease Association of America, and the Cooley's Anemia Foundation are additional resources for patients navigating coverage disputes.

Fight Back With ClaimBack

Casgevy represents a potential cure for sickle cell disease and beta-thalassemia. A denial letter should not stand between you and that possibility. ClaimBack helps patients build professional, evidence-based insurance appeal letters tailored to gene therapy and rare disease denials.

Start your appeal at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: Which Should You File?